Therapeutic effects of live attenuated mycobacteria delivered via the lungs

The administration of MTBVAC and BCG vaccines through intranasal routes directly act on the lungs and regulate the immune environment, solving the problem that the existing technology is difficult to reverse the established asthma, and achieving effective treatment of asthma and protection of tuberculosis.

CN114845732BActive Publication Date: 2024-11-08UNIV DE ZARAGOZA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080082198.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-09-26
Filing Date
2020-09-28
Publication Date
2024-11-08
Estimated Expiration
2040-09-28

AI Technical Summary

Technical Problem

Existing asthma treatments are difficult to effectively reverse established asthma status, especially the benefits of asthma through intradermal BCG vaccination are controversial, and the role of alveolar macrophages in the development of asthma is not fully focused on.

Method used

The live attenuated vaccines MTBVAC and BCG are administered through the intranasal route, which act directly on the lungs, regulate the immune environment associated with asthma, re-educated M2 macrophages to M1 type, and transform allergen-specific Th2 lymphocytes to Th1 type, This reduces asthma symptoms.

Benefits of technology

In different asthma models, intranasal MTBVAC and BCG significantly reduced eosinophils, restored inflammatory response, demonstrated their therapeutic effect in established asthma states, and showed protective effects on Mycobacterium tuberculosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003662718180000151
    Figure BDA0003662718180000151
  • Figure BDA0003662718180000152
    Figure BDA0003662718180000152
  • Figure HDA0003662718190000011
    Figure HDA0003662718190000011
Patent Text Reader

Abstract

The present invention relates to a live attenuated Mycobacterium tuberculosis composition for treating a human subject in need thereof, the composition comprising an isolated microorganism belonging to the MTBVAC strain of Mycobacterium tuberculosis, the isolated microorganism having: i) a PhoP-phenotype inactivated by genetic deletion of the Rv0757 gene, wherein the open reading frame (ORF) sequence of PhoP consists of SEQ ID NO 4; and ii) a deletion of a second gene Rv2930 (fadD26) that prevents PDIM production (PDIM-phenotype), wherein the open reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, wherein the composition is administered to the subject by pulmonary administration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to pharmaceutical compositions, such as vaccines, and methods of making and using such compositions. Background Art

[0002] According to the World Health Organization (WHO), asthma has reached epidemic levels, with more than 200 million asthma sufferers worldwide. Although particularly prevalent in developed countries, the incidence is also increasing rapidly in low- and middle-income situations. Over the past few decades, one of the most accepted explanations for the increase in asthma is the so-called "hygiene hypothesis," which suggests that one of the reasons behind this sharp increase is the result of a lower exposure of children to certain environmental factors (Strachan DP. Hayfever, hygiene, and household size. BMJ 1989; 299: 1259-60.). In this regard, exposure to certain microbes and mites during early life, such as those present on farms, appears to educate the immune system to acquire a higher tolerance to allergens (Stein MM, Hrusch CL, Gozdz J, Igartua C, Pivniouk V, Murray SE, et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med 2016; 375:411-21.).

[0003] Asthma is a heterogeneous disease characterized by chronic airway inflammation and airway remodeling. Although asthma may be associated with different types of inflammatory responses, type 2 inflammation is present in more than 80% of childhood asthma cases. T helper (Th) lymphocytes with a Th2 spectrum are present in most patients, producing cytokines such as IL-4, IL-5 or IL-13, which are the cause of some characteristic clinical symptoms. IL-5 plays a central role in the survival and recruitment of eosinophils, which are one of the main players in asthma, and its presence in saliva represents one of the most accepted biomarkers for diagnosing the disease. In addition, IL-4 and IL-13 trigger airway remodeling by inducing airway epithelial cell proliferation and exacerbating mucus production (Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers 2015; 1: 15025.).

[0004] In addition to adaptive responses, in the past few years, different studies have demonstrated the critical importance of the lung's intrinsic population for asthma triggering. In fact, presenting allergens through MHC-II molecules from antigen presenting cells (APCs) is essential for inducing allergen-specific T cells (Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-83.). Asthma is associated with the polarization of pathological macrophages toward the M2 phenotype (Girodet PO, Nguyen D, Mancini JD, Hundal M, Zhou X, Israel E, et al. Alternative Macrophage Activation Is Increased in Asthma. Am J Respir Cell Mol Biol 2016; 55: 467-75). M2 macrophages, or alternatively activated M2 macrophages, adopt regulatory skills and trigger an immunoregulatory environment that impairs Th1 responses and favors the expansion of Th2 cells (Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1 / M-2 macrophages and the Th1 / Th2 paradigm. J Immunol 2000; 164: 6166-73.). Therefore, elevated levels of M2 macrophages have been found in animal asthma models and samples from patients. Therapies targeting M2 macrophages have been shown to reduce allergic reactions (Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, Murray L, et al. Serum amyloid Pattenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol 2010; 126: 712-21e7.).

[0005] The current tuberculosis vaccine, BCG, is the most used vaccine in history. Since BCG has long been considered a vaccine that promotes a Th1 response, the benefits of intradermal BCG vaccination for asthma have been discussed for many years. Conclusions on this issue remain controversial, with different epidemiological studies showing opposing results.

[0006] Live and inactivated BCG vaccines and different mycobacterial components have been widely demonstrated to be effective against asthma in different animal models (Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G. Infection of micewith Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J Exp Med 1998; 187: 561-9. Lagranderie M, Abolhassani M, Vanoirbeek J, Lefort J, Nahori MA, Lapa ESJR, et al. M. bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models. J Allergy Clin Immunol 2008; 121: 471-8. Tsujimura Y, Inada H, Yoneda M, Fujita T, Matsuo K, Yasutomi Y. Effects of mycobacteria major secretion protein, Ag85B, on allergic inflammation in the lung. PLoS One 2014;9:e106807). However, most of these results were obtained when BCG was delivered before or simultaneously with allergen sensitization. Therefore, the ability of BCG to reverse established asthma has not been addressed, which is critical to elucidating the therapeutic potential of this vaccine as an asthma treatment. In addition, previous studies have mainly focused on the Th1 / Th2 response balance and have not focused on other branches of the immune system involved in asthma, such as alveolar macrophages, which appear to play a major role in the development of asthma.

[0007] MTBVAC is a live attenuated vaccine based on Mycobacterium tuberculosis (Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013; 31: 4867-73). It has been shown in different animal models to have stronger immunogenicity and protective effects against tuberculosis (Gonzalo-Asensio J, Marinova D, Martin C, Aguilo N. MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. Front Immunol. 2017 Dec 15;8:1803.doi:10.3389 / fimmu.2017.01803) and has been shown to be safe and immunogenic in human adults and neonatal populations (Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, et al. Safety of human immunisation with a live-attenuated M.tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 2015;3:953-62)(Tameris et al, Randomised controlled double blind dose-escalation infant trial of the live-attenuated M.tuberculosis vaccineMTBVAC. Lancet Respir Med 2019.IN PRESS).Currently, MTBVAC is being evaluated in two Phase IIa studies to determine an efficacy trial dose for the TB vaccine.

[0008] In the present invention, we evaluated the therapeutic effect of the live attenuated vaccines MTBVAC and BCG administered by the intranasal route in mice already sensitized to allergens in different models of acute asthma. We hypothesized that through a direct interaction between the bacteria and the lung compartment, the vaccine could modulate the immune environment associated with asthma. In this sense, our results showed that both vaccines were able to re-educate M2 macrophages induced by allergen administration to an M1 phenotype and to convert allergen-specific Th2 lymphocytes to Th1. Importantly, our data showed that both BCG and MTBVAC administered to allergen-challenged mice had a strong therapeutic effect when the disease was already established, demonstrating the potential of live attenuated tuberculosis vaccines as an asthma treatment. We also demonstrated the best protection of intranasal MTBVAC against challenge with Mycobacterium tuberculosis (M. tuberculosis), suggesting that the pulmonary route of administration is more advantageous not only for the treatment of asthma but also for the prevention of tuberculosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 Intranasal BCG and MTBVAC prevent allergic airway responses in allergen-sensitized mice. Eosinophils were measured by flow cytometry in an OVA-driven acute asthma model. Mice were treated with 10 6 CFU of BCG or 10 7 CFU of MTBVAC intranasal treatment. (A) Eosinophils were determined by flow cytometry as SSChighSiglecF+CD11b+CD11b- cells. Representative graphs are shown in Figure (B). Percentage of eosinophils in BAL and lungs in mice treated with MTBVAC (C) or BCG (D). The total number of leukocytes, eosinophils, neutrophils and alveolar macrophages (AM) in BAL determined by flow cytometry in mice treated with MTBVAC (E) or BCG (F). (E) Representative images of PAS-stained fixed lungs of untreated (1, 2) or BCG-treated (3, 4) OVA-challenged mice. Purple is stained mucosal material and goblet cells (G). The data in the figure represent the mean ± SEM from three independent experiments. At least 6 mice were used in each experiment per group. Results obtained by two-way ANOVA with Bonferroni post hoc test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

[0010] Figure 2 The therapeutic effects of BCG and MTBVAC on pulmonary eosinophilia are dose-dependent. Figure 1 The vaccine dose-response profile was evaluated in an acute model of OVA-induced asthma described in . Vaccinations at different doses of MTBVAC and BCG were compared to an untreated OVA positive control. A dose-response effect was observed when comparing different doses of vaccination, indicating a decrease in eosinophils in MTBVAC and BCG as the vaccination dose increased. Data in the figures are mean ± SEM from one independent experiment (n = 6 mice / group). Each group was compared to OVA-challenged mice by two-way ANOVA analyzed with Dunn's post hoc test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Notably, both BCG and MTBVAC reduced BAL( Figure 2 A) and lungs ( Figure 2 In both cases, BAL showed eosinophilia at 10 6 In the lung, the highest tested dose (MTBVAC 10 7 CFU, BCG is 10 6 ) achieved negative control levels of eosinophilia.

[0011] Figure 3 .Intranasal BCG infected lung resident macrophages and induced classical activation. (A) 10 6 CFU expressed GFP in BCG immune array mice. One month later, infected cells were monitored and characterized by flow cytometry. The expression of M1 polarization markers iNOS and CD86 was analyzed. Representative figures are shown in the figure. (B) The percentage of iNOS-, CD86- and MHC-positive alveolar macrophages in untreated or BCG-treated OVA-attacked. (C) Surface expression of M2 activation marker CD206. Representative overlay histograms of CD206 surface expression of the specified experimental groups are shown. The figure shows a comparison of the mean fluorescence intensity (MFI) corresponding to the expression level of CD206. (D) M1 and M2 activation markers measured in the lungs of untreated or BCG-treated OVA-attacked mice by qRT-PCR. The data in the figure are representative mean ± SEM from two independent experiments (B, C) or one experiment (D). At least 6 mice were used in each experiment per group. Obtained by unpaired single (B, C) or multiple (D) t-test of Student's: *p<0.05; **p<0.01; ***p<0.001.

[0012] Figure 4.Intranasal BCG reshapes allergen-specific responses to a Th1 profile. (A) Th1 and Th2 activation markers measured by qRT-PCR in the lungs of OVA-challenged mice that were untreated or treated with BCG one week after sensitization. (B) IL-5 determination in BAL. (C) IL-4 and IFNγ determination in lung explants (DG). Allergen-specific IL-4, IL-5, IL-13 and IFNγ produced by mediastinal lymph node cells after OVA stimulation ex vivo. Each point corresponds to the subtraction of the value obtained in the presence of OVA minus the value without allergen. (H, I) After stimulation with anti-CD3 / CD28 or with OVA ex vivo, cells producing IL-5 and IFNγ were observed by intracellular staining and flow cytometry. Representative figures are shown. The data in the figures are the pooled mean ± SEM from three independent experiments (BE, G) or one experiment (A, I). At least 6 mice were used per experiment per group. Obtained by multiple t-student test (A), one-way ANOVA with Bonferroni post hoc test (B, DG), and two-way ANOVA with Bonferroni post hoc test (C, I): *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

[0013] Figure 5 . Modulation of immune responses by MTBVAC. Analysis of Th2 vs. Th1 responses in an allergic acute asthma model. IL-5 and IFNγ- were analyzed in bronchoalveolar lavage (BAL) (A) and lymph nodes (B) as representative cytokines of Th2 and Th1 responses, respectively. (C) iNOS and Arg1 were analyzed in lung macrophages as representative molecules of M2 and M1 macrophage polarization responses, respectively. Intranasal MTBVAC treatment restored Th2 and M2 asthma-associated responses to Th1 and M1. Data in the figures are mean ± SEM from one independent experiment (n = 6 mice / group). Comparison of p<0.05; **p<0.01; ***p<0.001 was obtained by one-way ANOVA with Bonferroni post hoc test (A) and two-way ANOVA with Bonferroni post hoc test (B).

[0014] Figure 6.Intranasal BCG and MTBVAC restore established allergic airway responses. (A) Experimental scheme based on the OVA-induced chronic model. Mice were challenged with 10 μg of OVA intranasally twice a week from week 3 to week 13. The vaccine was delivered at week 9, halfway through the challenge phase. (B) Total number of eosinophils in the BAL at week 8, one week before vaccine immunization. This indicates that there was established eosinophilia before vaccine administration. (C) Total number of eosinophils in the BAL at week 13, 4 weeks after MTBVAC or BCG treatment. (E) Representative images of PAS-stained fixed lungs from OVA-challenged mice, untreated or MTBVAC-treated. The data in the figure are the mean ± SEM of representative experiments from at least two independent experiments. At least 6 mice were used per experiment per group. Results were obtained by Student's t-test (B, C), two-way ANOVA with Bonferroni post-test (D): *p<0.05; **p<0.01; ***p<0.001.

[0015] Figure 7 .MTBVAC restores asthma-related phenotypes in a model of established asthma induced by the relevant allergen house dust mite (HDM). (A) Scheme of the HDM-induced chronic model. Mice were challenged intranasally with 10 μg HDM twice a week for three consecutive weeks. The vaccine was delivered in week 4 and challenged intranasally with 10 g HDM for three consecutive days one month later. The day after the animals were sacrificed, (B) in another group sacrificed in week 3, eosinophils in the BAL were determined, confirming the presence of eosinophils when the vaccine was administered. The figure shows a comparison of the percentage of eosinophils in the BAL between weeks 3 and 7 in mice treated with untreated or BCG, MTBVAC (C). Lung remodeling and mucus secretion were assessed by PAS staining and histological evaluation. Representative images are shown in Figures (D, E), where Th2 cytokines IL-5, IL-4 and IL-13 were analyzed in BAL and lymph nodes after ex vivo stimulation with HDM. (F, G) The Th1 cytokine IFNγ- was analyzed in BAL and in lymph nodes after ex vivo stimulation with HDM. The data in the figure are the mean ± SEM from an independent experiment (n = 6 mice / group). By using one-way ANOVA with Bonferroni post hoc test (A, F, G) and two-way ANOVA with Bonferroni post hoc test (D, E), *p < 0.05; **p < 0.01; ***p < 0.001.

[0016] Figure 8MTBVAC is more efficiently nebulized than BCG in a clinical nebulizer. MTBVAC and BCG were nebulized using the clinical device OMRON U100 (A) and recovered into a known volume of sterile water in a wash bottle (B). (C, D) CFU loss in the nebulized fraction compared to the reservoir for MTBVAC (C) and BCG (D) in two independent experiments. (E) Nebulization effectiveness index calculated as the percentage of bacteria recovered in the nebulized fraction compared to the bacteria initially available in the GMP formulation.

[0017] Fig. 9 .MTBVAC is smaller than BCG. Representative electron microscopy images of BCG (A) and MTBVAC (B) are shown.

[0018] Fig.10 .MTBVAC reduces esophageal eosinophilia. Eosinophils in the esophagus were measured in an acute model of OVA-induced asthma, in which one group was treated with MTBVAC. Intranasal MTBVAC treatment significantly reduced eosinophilia. The figure shows the mean ± SEM of pooled data from two independent experiments (n = 6 mice per group per experiment). Obtained by one-way ANOVA with Bonferroni post hoc test: *p < 0.05.

[0019] Fig.11 .Intranasal MTBVAC improves protection against tuberculosis compared to BCG delivered by the classical subcutaneous route. Mice were vaccinated with BCG by the subcutaneous route (similar to the intradermal used in the clinic) or with MTBVAC by the intranasal route. Two months later, mice were challenged intranasally with a low dose of Mycobacterium tuberculosis strain H37Rv, and the bacterial load in the lungs was determined after 4 weeks. The figure shows the mean ± SEM of the pooled data from four independent experiments (n = 6 mice per group per experiment). Obtained by one-way ANOVA with Bonferroni post hoc test: ****p < 0.00001.

[0020] Fig.12 .A: OMRON U100 nebulizer used for the experiments performed for this figure. B: MTBVAC and BCG ONCOTICE CFU determined in the nebulized and reservoir fractions. C: Nebulization effectiveness index calculated as the percentage of bacteria recovered in the nebulized fraction compared to the bacteria contained in the reservoir. Each point corresponds to the result obtained using a different filter. The data in the figure represent the mean ± SEM from six independent MTBVAC nebulizations and three BCG ONCOTICE nebulizations. Obtained by t-Student's test: *p < 0.05. DETAILED DESCRIPTION

[0021] definition

[0022] "MTBVAC strain" will be used to refer to an isolated strain of Mycobacterium tuberculosis microorganism that has deleted the Rv0757 gene in the Mycobacterium tuberculosis Mt103 clinical strain and additionally comprises a deletion of the Rv2930 (fadD26) gene. Thus, the strain presents two independent mutations derived from Mycobacterium tuberculosis, the independent phoP deletions not affecting the properties of the vaccine derived from the inactivation of said genes. Thus, the "MTBVAC strain" is characterized in that the production of PDIM is inactivated by the deletion of the Rv2930 (fadD26) gene, and the strain is therefore characterized in that it comprises a deletion of the Rv2930 and Rv0757 genes.

[0023] Therefore, it should be noted that the MTBVAC strain was constructed to contain two independent irreversible deletion mutations, without antibiotic markers, and fulfilled the first Geneva consensus safety requirement for advancing live mycobacterial vaccines to Phase I clinical evaluation. The MTBVAC strain was genetically engineered to be phenotypically and functionally similar to its prototype, SO2. S02 is a tagged Mt103 phoP mutant (Mt103phoP::kmr) obtained by insertion of a kanamycin resistance cassette (kmr). In addition to the engineered PhoP-deficient phenotype, S02 has an acquired spontaneous loss in PDIM biosynthesis (see Dessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo & Carlos Martin (2017) MTBVAC from discovery to clinicaltrials in tuberculosis-endemic countries, Expert Review of Vaccines, 16:6, 565-576, DOI:10.1080 / 14760584.2017.1324303). Figure 2 ), a process that is common in Mycobacterium tuberculosis and is the result of repeated laboratory subculture and operational practices.

[0024] The MTBVAC strain was constructed according to a stepwise approach. First, an unmarked deletion of fadD26 was introduced in SO2, generating SO2ΔfadD26. As a result, an unmarked deletion of phoP in SO2ΔfadD26 generated the MTBVAC strain. To construct MTBVAC, a suicide plasmid with a deletion of fadD26 and phoP genes was used, with the deletion region interrupted by a hygromycin resistance marker (hygr) flanked by res sites (res::hygr::res). Upon recognition of the res site, the γδ-resolvase from Escherichia coli (E. coli) catalyzes the excision of the antibiotic resistance cassette, leaving a residual copy of the res "scar" in place of the deletion (Malaga, et al. 2003); the res site does not contain any exogenous coding sequence. The final construct SO2ΔfadD26::ΔphoP was named the MTBVAC strain. In the MTBVAC strain, the introduction of the unmarked fadD26 deletion ensured that PDIM biosynthesis was genetically stably eliminated. The size of the resulting gene fadD26 deletion contains 1511 bp and leads to the complete inactivation of this essential gene in PDIM biosynthesis. The wild-type gene is 1752 bp (583 amino acids). A residual res scar is left during the excision of hygr by the γδ-resolvase. Because of this deletion, the transcription levels of the next five genes in the PDIM locus (fadD26-ppsE) are reduced, and PDIM biosynthesis in MTBVAC is completely eliminated (Ainhoa ​​Arbués PhD thesis). The PDIM locus in Mycobacterium tuberculosis contains 13 genes that are clustered on a 50 kb fragment of the chromosome. This region is the largest operon in the Mycobacterium tuberculosis genome (Camacho, et al. 2001; Camacho, et al. 1999; Cox, et al. 1999; Trivedi, et al. 2005).

[0025] In M. tuberculosis, phoP (744 bp) is located upstream of phoR (1458 bp), and both genes are transcribed in the same direction. The replacement of the 94 bp deletion within the phoP gene with a residual res site requires the presence of multiple STOP codons, which, on the other hand, results in a lack of translation of the DNA binding domain of PhoP (corresponding to 92 amino acids) in MTBVAC.

[0026] The absence of phoP and fadD26 genes in MTBVAC can be detected / localized using the RT-PCR presence / absence method. This method uses fluorescence-based PCR reagents (primers and probes) to indicate the presence of the res site in the ΔphoP and ΔfadD26 genes and the absence of wild-type phoP and fadD26 genes.

[0027] In the following, we provide: the open reading frame (ORF) sequence of the fadD26 gene in Mt103 a) and in MTBVAC (ΔfadD26) b); and the ORF sequence of the phoP gene in Mt103 c) and in MTBVAC (ΔphoP) d). The nucleotide sequences corresponding to the deleted gene regions in fadD26 (a) and phoP (c) are indicated in lowercase letters; the residual res site is highlighted in gray. For the fluorescence-based PCR detection method, the primers for each target are underlined and the Taq-man probe is shown in bold.

[0028] a) Wild-type fadD26 gene in Mt103

[0029] SEQ ID NO 1.

[0030] ATGCCGGTGACCGACCGTTCAGTGCCCTCTTTGCTGCAAGAGAGGGCCGACCAGCAGCCTGACAGCACTGCATATACGTACATCGACTACGGATCCgaccccaagggatttgctgacagcttgacttggtcgcaggtctacagtcgtgcatgcatcattgctgaagaactcaagttatgcgggttacccggagatcgagtggcggtttta gcgccacaag gactggaat a gggcgcac ttcaggctggatttatcgcg

[0031] b) ΔfadD26 in MTBVAC

[0032] SEQ ID NO 2.

[0033] ATGCCGGTGACCGACCGTTCAGTGCCCTCTTTGCTGCAAGAGAGGGCCGACCAGCA GCCTGACAGCAC TGCATATACG TACA GATATCGAAGTCACACAGCCTGCGGGTGGCCGATCTCGTTCTGGTGTCACCTGGTTCGATTCCCATCACCACCAGCGGCAAGATCCGGCGGTCAGCCTGCGTCGAACGCTATCGCAGCGACGGCTTCAAGCGGCTGGACGTAGCCGTATGA

[0034] c) Wild - type phoP gene in Mt103

[0035] SEQ ID NO 3.

[0036] ATGCGGAAAGGGGTTGATCTCGTGACGGCGGGAACCCCAGGCGAAAACACCACACCGGAGGCTCGTGTCCTCGTGGTCGATGATGAGGCCAACATCGTTGAACTGCTGTCGGTGAGCCTCAAGTTCCAGGGCTTTGAAGTCTACACCGCGACCAACGGGGCACAGGCGCTGGATCGGGCCCGGGAAACCCGGCCGGACGCGGTGATCCTCGATGTGATGATGCCCGGGATGGACGGCTTTGGGGTGCTGCGCCGGCTGCGCGCCGACGGCATCGATGCCCCGGCGTTGTTCCTGACGGCCCGTGACTCGCTACAGGACAAGATCGCGGGTCTGACCCTGGGTGGTGACGACTATGTGACAAAGCCCTTCAGTTTGGAGGAGGTCGTGGCCAGGCTGCGGGTCATCCTGCGACGCGCGGGCAAGGGCAACAAGGAACCACGTAATGTTCGACTGACGTTCGCCGATatcgagctcgacgaggagaccc acgaagtgtggaaggcgg gccaaccgg ccgaattcac cctgctgcgctatttcgtG ATCAACGCGGGCACCGTGCTGAGCAAGCCTAAGATTCTCGACCACGTTTGGCGCTACGACTTCGGTGGTGATGTCAACGTCGTCGAGTCCTACGTGTCGTATCTGCGCCGCAAGATCGACACTGGGGAGAAGCGGCTGCTGCACACGCTGCGCGGGGTGGGCTACGTACTGCGGGAGCCTCGATGA

[0037] d) ΔphoP in MTBVAC

[0038] SEQ ID NO 4.

[0039] ATGCGGAAAGGGGTTGATCTCGTGACGGCGGGAACCCCAGGCGAAAACACCACACCGGAGGCTCGTGTCCTCGTGGTCGATGATGAGGCCAACATCGTTGAACTGCTGTCGGTGAGCCTCAAGTTCCAGGGCTTTGAAGTCTACACCGCGACCAACGGGGCACAGGCGCTGGATCGGGCCCGGGAAACCCGGCCGGACGCGGTGATCCTCGATGTGATGATGCCCGGGATGGACGGCTTTGGGGTGCTGCGCCGGCTGCGCGCCGACGGCATCGATGCCCCGGCGTTGTTCCTGACGGCCCGTGACTCGCTACAGGACAAGATCGCGGGTCTGACCCTGGGTGGTGACGACTATGTGACAAAGCCCTTCAGTTTGGAGGAGGTCGTGGCCAGGCTGCGGGTCATCCTGCGACGCGCGGGCAAGGGCAA CAAGGAACCACGTAATGTTC GA CTGA GATCAACGCGGGCACCGTGCTGAGCAAGCCTAAGATTCTCGACCACGTTTGGCGCTACGACTTCGGTGGTGATGTCAACGTCGTCGAGTCCTACGTGTCGTATCTGCGCCGCAAGATCGACACTGGGGAGAAGCGGCTGCTGCACACGCTGCGCGGGGTGGGCTACGTACTGCGGGAGCCTCGATGA

[0040] SO2 has a thorough and complete preclinical history, demonstrating a solid safety profile and attenuated toxicity profile compared with BCG and promising efficacy in relevant animal models. Fortunately, most of these preclinical studies have been reproduced with MTBVAC, confirming the functional characteristics and biological activity of the dual attenuated PhoP-PDIM-phenotype. Lipid profile analysis has shown that MTBVAC and its prototype SO2 are phenotypically equivalent, lacking DAT, PAT, and PDIM.

[0041] On the other hand, in the following of the present invention, BCG will be used to refer to the current vaccine, which has been used against tuberculosis since 1921. This is a live attenuated vaccine derived from Mycobacterium bovis (M. bovis) that has lost its virulence after laboratory subculture and which is now known to have more than a hundred deleted genes (Behr, MABCG—different strains, different vaccines Lancet Infect Dis 2002, 2(2), 86-92).

[0042] In the following of the present invention, H37Rv will be used to refer to the sequenced pathogenic Mycobacterium tuberculosis strain, and Cole et al. referred to these genes as Rv (Ref Cole et al 1998 Deciphering the biology of M. tuberculosis from the complete genome sequence. Nature 393: 537-544).

[0043] From the following of the present invention, Mt103 will be used to refer to the clinical isolate of Mycobacterium tuberculosis (Camacho et al. 1999 Identification of a virulence gene cluster of M. tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 34: 257-267). From the following of the present invention, PDIM- strains will be used to refer to strains of Mycobacterium tuberculosis that are unable to synthesize the Mycobacterium tuberculosis complex of the important lipid phthiocerol dimycocerosate associated with the pathogenicity of Mycobacterium tuberculosis.

[0044] In the following of the present invention, M. tuberculosis phoP- will be used to refer to M. tuberculosis strains that have been inactivated by deletion of the Rv0757 gene between the EcoRV-BspEI sites, which phenotype is phoP-PDIM+.

[0045] From the following in the context of the present invention, Rv2930 (fadD26) will be used to refer to the gene located at the beginning of the operon responsible for the synthesis of tuberculin hydroxylated amine (PDIM) (Camacho et al.), and whose elimination in M. tuberculosis confers a stable PDIM-phenotype.

[0046] describe

[0047] The data available in the literature demonstrate the major role of pulmonary intrinsic cells in the development of asthma. Specifically, in animal models and humans, alternatively activated macrophages or M2 macrophages are elevated in the lungs of asthmatic individuals. The reason behind this pathological macrophage polarization is unclear. A reasonable explanation is that allergens can directly cause alveolar epithelial damage, and macrophages are activated as a response to damage to induce wound healing reactions (Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-37). M2 is a simplified term that includes different macrophage subsets with regulatory skills. Therefore, three different types of M2 macrophages, M2a, M2b and M2c, have been defined, each with its own characteristics. In the specific case of M2a macrophages, their presence is associated with the induction of Th2 adaptive responses (Saradna A, Do DC, Kumar S, Fu QL, Gao P. Macrophage polarization and allergic asthma. Transl Res 2018; 191: 1-14). With regard to allergic asthma, M2a macrophages can contribute to triggering allergen-specific T cell responses in at least two different ways. First, since they express high levels of MHC-II molecules once activated, they can present allergen-derived peptides to T lymphocytes, and secondly, they secrete cytokines such as IL-4, which drive T cell response polarization toward the Th2 spectrum (von Bubnoff D, Geiger E, Bieber T. Antigen-presenting cells in allergy. J Allergy Clin Immunol 2001; 108: 329-39). Therefore, because exacerbated M2 macrophage activation appears to be important in the inflammatory response in asthma, this represents an attractive opportunity to design novel immunomodulatory treatments that target this imbalance in lung macrophage populations.

[0048] In the present invention, we have evaluated the therapeutic potential of live attenuated tuberculosis vaccines delivered by the intranasal route in different preclinical models of asthma. Our results are very robust. In short-term and long-term acute models induced by different allergens, and even in the case of established asthma, intranasal BCG and MTBVAC were able to restore asthma-related responses in all cases tested ( Figure 1 , Figure 2 , Figure 6 , Figure 7Our data clearly demonstrate that BCG and MTBVAC impair M2 macrophages associated with allergen exposure ( Figure 3 , Figure 5 ). A possible mechanism behind this inhibition could depend on the ability of the vaccine to activate macrophages in a classical manner (or M1 phenotype), possibly due to their natural intracellular state. Thus, BCG and MTBVAC are efficiently internalized by alveolar macrophages after immunization, leading to the expression of markers such as iNOS and the secretion of cytokines such as IL-1β, TNFα and IL-12, thereby generating an antagonist of the inflammatory response against that produced by alternatively activated macrophages. Importantly, our analysis of BCG bacteria expressing GFP showed that not only infected macrophages but also uninfected cells adopt the M1 phenotype. These suggest that initially infected macrophages generate a series of signals that also activate bystander neighbours, favoring an amplified response to a milieu that plays a balancing role in the fight against asthma.

[0049] The benefits of BCG in patients with asthma have been extensively studied clinically in observational studies comparing asthma prevalence in BCG vaccinated populations (Arinho E, Schor D, Veloso M, Lima M. BCG scar diameter and asthma: a case-control study. J Allergy Clin Immunol 2000; 106: 1199-200), and in interventional studies in which two groups received BCG or placebo and reported asthma symptoms and were compared between the two groups (Choi IS, Koh YI. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann Allergy Asthma Immunol 2002; 88: 584-91). The data are controversial, with studies showing opposing results. A few years ago, a report comparing different published studies using meta-analysis showed no clear association between intradermal BCG vaccination and a lower risk of developing asthma (Arnoldussen DL, Linehan M, Sheikh A. BCG vaccination and allergy: a systematic review and meta-analysis. J Allergy Clin Immunol 2011; 127: 246-53, 53e1-21). A reasonable hypothesis to explain this apparent discordance between clinical data and ours could be that the beneficial effects of BCG are organ dependent, and therefore BCG needs to be physically present in the lungs to induce an effective anti-asthmatic response. In fact, subcutaneous BCG has no protective effect against asthma in mice (Lagranderie M, Abolhassani M, Vanoirbeek J, Lefort J, Nahori MA, Lapa ESJR, et al. Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models. J Allergy Clin Immunol 2008; 121: 471-8), a result we have confirmed with MTBVAC. This is clearly to be expected based on our observation that BCG must interact with lung resident macrophages to reshape their activated phenotype.Searching the literature, there are some interesting data that support this hypothesis. Unlike what is reported for BCG, the data showing a lower prevalence of asthma in patients with tuberculosis infection seem more reliable. In this regard, a significant correlation has been found between a lower incidence of asthma and notified cases of TB (von Mutius E, Pearce N, Beasley R, Cheng S, von Ehrenstein O, Bjorksten B, et al. International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema. Thorax 2000; 55: 449-53.). A study conducted in individuals with latent TB infection (LTBI) showed a close association between a positive tuberculosis skin test (TST) and a lower prevalence of different types of allergies. Interestingly, in the case of asthma, the authors found a significant reduction in asthma incidence in the group with the highest TST values, suggesting a correlation between the magnitude of the TB-specific immune response and the degree of nonspecific protection (Obihara CC, Kimpen JL, Gie RP, Lill SW, Hoekstra MO, Marais BJ, et al. M. tuberculosis infection may protect against allergy in atuberculosis endemic area. Clin Exp Allergy 2006; 36: 70-6.). Of note, we recently demonstrated a protective effect against asthma in tuberculosis-infected mice (Tarancón R, Uranga S, Martín C, Aguiló N. Mycobacterium tuberculosis infection prevents asthma and abrogateseosinophilopoiesis in an experimental model Allergy. 2019 May 22. doi: 10.1111 / all.13923). Since M. tuberculosis infection is usually acquired via the respiratory route (and BCG is administered intradermally), we can conclude that our results with live attenuated vaccine delivery in the lungs may reflect natural nonspecific protection that already occurs in nature.

[0050] Allergen-specific CD4+T cells are thought to play a central role in asthmatic inflammation. The use of allergen-MHC-II tetramers has allowed the characterization of allergen-specific CD4+T cells in asthmatic individuals, resulting in the discovery of tetramer-positive T cell clones expressing central memory markers (Kwok WW, Roti M, Delong JH, Tan V, Wambre E, James EA, et al. Direct ex vivo analysis of allergen-specific CD4+T cells. J Allergy Clin Immunol 2010; 125: 1407-9e1.). These long-lived T cells ultimately lead to the persistence of asthma throughout the life cycle. After allergen exposure, specific memory CD4+T cells migrate to the lungs, where they effectively recognize allergen-derived peptides presented by APCs and respond rapidly by secreting Th2-related cytokines, leading to asthmatic inflammatory responses. Therefore, therapies seeking relief from asthma should focus on hindering allergen-specific Th2 memory cells. For example, immunotherapy based on low-level allergen epitope exposure works by inducing anergy to allergen-specific Th2 T cells (O'Hehir RE, Prickett SR, Rolland JM. T Cell Epitope Peptide Therapy for Allergic Diseases. Curr Allergy Asthma Rep 2016; 16: 14.). Our analysis of OVA-specific T cells in draining lymph nodes showed that intranasal BCG and MTBVAC had a strong effect on OVA-specific Th2 cells ( Figure 4 , Figure 5 Intracellular staining and flow cytometry allow direct visualization of cytokine-producing cells, which showed that the IL-5-producing T cell population in the OVA group was significantly reduced after BCG treatment, provided that an OVA-specific IFNγ-producing cell population appeared ( Figure 4 H. Figure 4 I). This suggests that live mycobacteria can reshape the phenotype of T cells involved in asthma responses.

[0051] In the past few years, new experimental immunotherapy for asthma has emerged, mainly based on blocking specific pathways that cause asthma-induced inflammation, such as IL-4, IL-5, IL-13 or IgE, which are shown as positive results in many cases. However, these studies have also demonstrated that the efficacy achieved by inhibiting a single pathway is usually partial. For example, IL-5 specific therapy substantially inhibits eosinophilia, while the results for other metrics (such as lung function) are less favorable (Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-9.). Since asthma is a highly complex disease, we speculate that the more comprehensive approach proposed in this study can more effectively handle different aspects of pathology.

[0052] MTBVAC is a novel tuberculosis vaccine that has been shown to be safe in human neonates and adults via the intradermal route. The results presented here demonstrate the ability of intranasal MTBVAC to restore asthma-associated inflammatory responses. Therefore, pulmonary MTBVAC may represent an attractive approach for allergic asthma with several advantages over BCG, which are briefly summarized below.

[0053] First, data from clinical trials suggest that intradermal MTBVAC has lower reactogenicity than BCG (Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, et al. Safety of human immunisation with a live-attenuated M. tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 2015; 3: 953-62), which may be related to the more effective clearance observed in the present invention. It is worth noting that, unlike BCG, which is resistant to isoniazid and pyrazinamide, MTBVAC has been shown to be fully sensitive to current tuberculosis antibiotics.

[0054] Secondly, as already discussed above, a reasonable hypothesis to explain our findings is that the beneficial effects of BCG and MTVBAC are organ-dependent, and therefore both need to be physically present in the lungs to induce an effective anti-asthmatic response. Therefore, pulmonary delivery is necessary to induce therapeutic efficacy against asthma. Through the pulmonary route, drugs can be administered in two main ways: one is intranasal administration, which has anatomical limitations such as narrow airway lumen; the other is oral inhalation administration. Better results can be expected through oral inhalation administration because it allows the administration of very small particles with a concentration loss of only 20%, compared to 85% through the nasal route. Oral inhalation administration can be further divided into intratracheal instillation and intratracheal inhalation. The most commonly used method in the laboratory is intratracheal instillation. In intratracheal instillation, a small amount of drug solution or dispersion is delivered to the lungs through a dedicated syringe. This provides a rapid and quantifiable method for delivering drugs to the lungs. Local drug deposition is achieved through a relatively small absorption area. Therefore, the instillation process is very simple, inexpensive, and the drug distribution is uneven. In preclinical animal studies, intratracheal instillation is often used to assess pulmonary absorption and systemic bioavailability, especially in terms of the precise dose and effectiveness associated with this method. However, intratracheal instillation is not a physiological route for application, and the results obtained from these studies may not be transferable to aerosol applications in humans. In contrast, the inhalation method uses aerosol technology, through which we can obtain a more uniform distribution and greater penetration.

[0055] Therefore, in the present invention, we used the aerosol nebulizer device OMRONU100 ( Figure 8 A) The effects of aerosolization of BCG and MTBVAC were evaluated. This should be the best route for clinical administration of live attenuated vaccines, which can not only prevent asthmatic inflammatory responses but also restore them, so it may have potential therapeutic applications for administration in human patients. Figure 8 It was shown that MTBVAC was more effectively nebulized than BCG in this clinical nebulizer. The BCG and MTBVAC GMP batches tested in the study contained 1.7 × 10 7 CFU / ml and 1.1×10 7 CFU / ml. After 5 minutes of atomization, the amount of bacteria recovered was: MTBVAC was 1.98×10 6 CFU( Figure 8 C), BCG is 3.3×10 4 CFU( Figure 8 D). The average nebulization effectiveness index from two independent experiments was calculated as the percentage of bacteria recovered in the nebulized fraction compared to the bacteria initially available in the reservoir for MTBVAC and BCG, 15% and 0.15%, respectively ( Figure 8 E).

[0056] Importantly, we Figure 2 The data presented in indicate that the therapeutic effects of BCG and MTBVAC on allergen-induced eosinophilia are strongly dose-dependent, and therefore it is critical that a critical dose of vaccine reaches the lungs to reduce eosinophil infiltration. View Figure 2 As a result, we can assume that 10 6 CFU will be the optimal therapeutic dose for both vaccines.

[0057] Taking into account the data obtained from the nebulization studies under defined experimental conditions, this dose was only achievable with MTBVAC, whereas with the BCG preparation we nebulized only about 3% of this optimal dose of bacteria. Therefore, we can conclude that the therapeutic dose with MTBVAC can be achieved using the inhalation method via aerosol using clinical equipment, whereas such a therapeutic dose cannot be achieved with BCG.

[0058] These differences can be explained by the different sizes of BCG and MTBVAC observed in electron microscopy images ( Fig. 9 ). MTBVAC bacilli are shorter than 1 μm, whereas BCG is longer than 2 μm. In addition, our observations in the laboratory indicate that BCG is more likely to form agglomerates than MTBVAC when the vaccine is incubated in the absence of detergents (as in industrial production). As the average aerosol particle size from clinical nebulizers is generally about 5 μm, we believe that these two factors, bacterial size and agglomeration, may explain the difference in nebulization efficacy between BCG and MTBVAC.

[0059] Our results also showed that in the OVA acute asthma model, eosinophil infiltration was also present in the esophagus, which was avoided when MTBVAC was administered intranasally ( Fig.10 These data suggest that live attenuated mycobacteria may be useful in treating other forms of pathogenic eosinophilia, such as eosinophilic esophagitis (EoE), in addition to allergic asthma.

[0060] The present invention describes for the first time the therapeutic efficacy of live attenuated MTBVAC mycobacteria induced by pulmonary delivery of MTBVAC by disrupting the pulmonary immune environment, preferably when MTBVAC is administered by the pulmonary route by inhalation using aerosol technology. Fig.11 It was also described in that MTBVAC pulmonary delivery improved protection against tuberculosis compared with BCG delivery by the classical subcutaneous route.

[0061] Thus, a first aspect of the present invention relates to a live attenuated Mycobacterium tuberculosis composition for treating a human subject in need thereof (composition of the present invention), the composition comprising an isolated microorganism belonging to the MTBVAC strain of Mycobacterium tuberculosis, the isolated microorganism having: i) a PhoP- phenotype inactivated by genetic deletion of the Rv0757 gene, wherein the open reading frame (ORF) sequence of PhoP consists of SEQ ID NO 4; and ii) a deletion of a second gene Rv2930 (fadD26) preventing PDIM production (PDIM- phenotype), wherein the open reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, wherein the composition is administered to the subject by pulmonary delivery. Preferably, the composition is administered to the subject via pulmonary delivery by inhalation using aerosol technology.

[0062] Preferably, the composition of the first aspect of the invention is a lyophilized composition, which further comprises certain components (e.g., specific stabilizers, fillers and buffers) that have been found to be advantageous for preparing a lyophilized MTBVAC strain vaccine. The present invention also relates to reconstituted vaccines and methods of prevention and treatment using the composition described in the first aspect of the invention, provided that the composition is administered to the subject via pulmonary delivery, preferably by inhalation using aerosol technology. The compositions and methods of the present invention are further described below.

[0063] In a preferred embodiment of the first aspect of the present invention or any preferred embodiment thereof, the composition is characterized in that the composition comprises at least 10 5 cfu to 10 6 cfu of isolated microbial strains. Preferably, the composition comprises 10 6 cfu to 10 7 cfu of isolated microbial strains.

[0064] In a second aspect of the invention, the vaccine composition of the first aspect of the invention can be administered as a primary prophylactic to subjects at risk of infection with Mycobacterium tuberculosis or at risk of developing tuberculosis by the pulmonary route, preferably by inhalation using aerosol technology, or can be used as a secondary agent in the treatment of infected patients. Because the strains of these compositions are attenuated, these compositions are particularly suitable for administration to "risk individuals", such as newborns, children, adolescents, adults and the elderly. Such vaccines can also be used in veterinary settings.

[0065] In the third aspect of the invention, the vaccine composition of the first aspect of the invention can be administered as a prophylactic agent to a subject at risk of suffering from an allergic reaction, preferably as a prophylactic agent targeting M2 macrophages to reduce allergic reactions, more preferably as a prophylactic agent to a subject at risk of suffering from asthma, especially allergic asthma, or a subject at risk of developing asthma, especially allergic asthma, by the pulmonary route, preferably by inhalation using aerosol technology; or the vaccine composition of the first aspect of the invention can be used as a medicament for treating patients with allergic reactions, preferably by targeting M2 macrophages to reduce allergic reactions, more preferably for treating asthma, especially allergic asthma. Because the strains of these compositions are attenuated, these compositions are particularly suitable for administration to "risk individuals", such as newborns, children, adolescents, adults and the elderly. This vaccine can also be used in veterinary settings.

[0066] A preferred embodiment of the second aspect of the invention relates to the composition of the first aspect of the invention for immunizing an individual against symptoms caused by tuberculosis. It should be noted that the vaccine may also be suitable for the treatment of bladder cancer as well as for the treatment or prevention of TB, or may be suitable as a carrier or adjuvant. Preferably, the individual is immunized against symptoms caused by TB.

[0067] In another preferred embodiment of the second aspect of the invention, the composition of the first aspect is administered for prophylaxis in newborns at risk of infection with Mycobacterium tuberculosis or at risk of developing TB disease against infection caused by the Mycobacterium tuberculosis complex, preferably Mycobacterium tuberculosis.

[0068] In another preferred embodiment of the second aspect of the present invention, the composition of the first aspect is administered for prevention or protection (including booster vaccination) in human non-neonates (e.g., children, adolescents and adults) at risk of infection with Mycobacterium tuberculosis against infection caused by the Mycobacterium tuberculosis complex, preferably Mycobacterium tuberculosis.

[0069] In another preferred embodiment of the second aspect of the invention, the composition of the first aspect is administered for the prevention or protection against the development of clinical symptoms associated with active disease caused by Mycobacterium tuberculosis complex, preferably Mycobacterium tuberculosis, in human non-neonates (e.g. children, adolescents and adults) at risk of developing TB disease and suffering from latent tuberculosis infection.

[0070] In another preferred embodiment of the second aspect of the invention, the composition of the first aspect is administered as an adjunct to the treatment of latent and / or active TB infected human neonates and human non-neonates (eg children, adolescents and adults).

[0071] In another preferred embodiment of the second aspect of the present invention, the composition of the first aspect is used for booster vaccination or booster administration in preventive treatment or protective treatment in human non-neonates (e.g., children, adolescents, and adults) at risk of infection with Mycobacterium tuberculosis to resist infection caused by Mycobacterium tuberculosis complex, preferably Mycobacterium tuberculosis. In this sense, it should be noted that after the initial immunization, booster injection or booster administration is a re-exposure to the immunizing antigen. This is intended to increase the immunity to the antigen to a protective level after the memory for the antigen decreases over time.

[0072] Throughout the specification and claims, the term "comprising" and its variants are not meant to exclude other technical features, additives, components or steps. For those skilled in the art, other objects, advantages and features of the present invention will be derived in part from this specification and in part from the time of implementing the present invention. The following examples and drawings are provided by way of non-limiting illustrative embodiments of the present invention.

[0073] Example

[0074] method

[0075] bacteria

[0076] BCG Danish SSI (Pfizer), BCG Pasteur (strain 1173P2, Pasteur Institute, Paris, France), MTBVAC (University of Zaragoza) strains were grown at 37°C in Middlebrook 7H9 broth (Difco) supplemented with ADC 10% (Difco) and 0.05% (v / v) Tween-80 (Sigma), or solid Middlebrook 7H11 (Difco) supplemented with ADC 10%. BCG Pasteur and MTBVAC were transformed with the replicative pJKD6 plasmid encoding green fluorescent protein (GFP) (gift from Luciana Leite, Butantan Institute, Brazil). Bacterial suspensions for vaccination were prepared in PBS from glycerol stocks previously quantified by plating serial dilutions. For bacterial quantification, bacterial suspensions were serially diluted and plated on agar medium 7H10 supplemented with ADC.

[0077] Animal studies

[0078] All mice were kept under controlled conditions and observed for any signs of disease. The experimental work complied with European and national directives for the protection of experimental animals and was approved by the Ethics Committee from University of Zaragoza (protocol PI22 / 15).

[0079] To induce OVA-specific asthma, 8- to 10-week-old female C57BL / 6 mice (Janvier Biolabs) were sensitized by two intraperitoneal injections of 50 μg of hen egg ovalbumin (lyophilized powder, ≥98% (Sigma)) and 2 mg of aluminum hydroxide (Sigma, St. Louis, MO) at one-week intervals. One week later, 10 μl of ... 6 Mice were immunized intranasally with CFU-specified vaccines. In the acute model, animals were challenged intranasally with 100 μg OVA in sterile PBS for 3 consecutive days 4 weeks after vaccination, and the animals were humanely sacrificed the next day. In the chronic model, mice were challenged intranasally with 10 μg OVA twice a week for eight weeks three weeks after immunization. In this case, the vaccine was administered at week 9 of the process, halfway through the challenge phase. For HDM-induced chronic asthma, mice were challenged intranasally with 10 μg HDM twice a week for three consecutive weeks. The vaccine was delivered in week 4, and one month later, 10 μg HDM was challenged intranasally for three consecutive days. The next day after this, the animals were sacrificed.

[0080] For bronchoalveolar lavage (BAL) collection, the trachea was cannulated and BAL was performed with 0.8 ml ice-cold PBS. The supernatant was separated from the cells by centrifugation at 4500 xg for 5 minutes.

[0081] Lungs were removed aseptically. To obtain a cell suspension, lungs were added to HEPES buffer (HEPES 10mM; NaCl 0.15M; KCl 5mM; MgCl2 1mM; CaCl2 1.8mM pH 7.4) containing collagenase D 100mg / ml (Roche) and DNAseI 400IU (AppliChem), incubated at 37°C for 30 minutes, and homogenized using a GentleMACS (Miltenyi Biotech) dissociator according to the manufacturer's instructions with a lung-specific program. Afterwards, residual erythrocytes were lysed using an erythrocyte lysis buffer (Sigma). In the case of histological analysis, lungs were fixed for 24 hours with 40% formaldehyde before the staining procedure.

[0082] Mediastinal lymph nodes were aseptically removed and mechanically disrupted for cell collection and then filtered to eliminate tissue remnants.

[0083] The esophagus was removed aseptically and transected. Then, the esophagus was added to HEPES buffer (HEPES 10mM; NaCl 0.15M; KCl 5mM; MgCl2 1mM; CaCl2 1.8mM pH 7.4) containing collagenase D 100mg / ml (Roche) and DNAseI 400IU (AppliChem), incubated at 37°C for 30 minutes, and homogenized. Afterwards, the homogenate was filtered to eliminate tissue residues.

[0084] Flow cytometric analysis

[0085] 10 6 Lung cells or BAL cells were incubated with Fc receptor blocker (Miltenyi Biotech) for 15 min at 4°C. The presence of eosinophils, neutrophils, and macrophages was then determined by extracellular staining with the following antibodies: CD45-FITC, siglecF-APC, Ly-6G-Vioblue from Miltenyi Biotech; and CD11c-PE, CD11b-PerCP / Cy5.5 from BD Biosciences. Eosinophils were defined as SSC 高 CD45 + CD11b + Siglec + CD11c - cells; neutrophils are CD45 + 6G + CD11b + CD11c - cells; and alveolar macrophages are CD45 + Siglec + CD11c + CD11b Dim cell.

[0086] For intracellular staining (ICS), after labeling membrane proteins with the above antibodies, except for MHCII-Vioblue (Miltenyi) and CD206-APC and CD86-PE (BD Biosciences), cells were fixed and permeabilized with the FoxP3 staining kit (Miltenyi Biotech) according to the manufacturer's instructions. For intracellular antibodies, we used iNOS-APC and iNOS-PE (Miltenyi), and Arg1-APC (eBiosciences). Cells were acquired using a Gallios flow cytometer (Beckman Coulter) and analyzed using Weasel software.

[0087] Cytokine analysis

[0088] Quantification of IL-5, IL-4, IL-13 and IFN-γ was performed using specific commercial ELISA kits according to the manufacturer's instructions (Mabtech Biotech). Cytokine assays in the lung were performed from organ explants. These were prepared by cutting the lung into small pieces and incubating overnight in 0.5 ml of culture medium at 37°C.

[0089] To analyze OVA or HDM-specific responses, mediastinal lymph nodes were removed aseptically and mechanically disrupted to collect cells. 2 × 10 6 Cells were incubated for 96 hours with or without OVA 1mg / ml or HDM 10ug / ml. Then, supernatants were collected to determine cytokine concentrations. The OVA-specific response of each cytokine was calculated as the difference between the cytokine concentration obtained after OVA stimulation minus the unstimulated control. For ICS, cells were incubated for 24 hours with 1mg / ml OVA or 1μg / ml anti-CD3 / CD28 (BD Biosciences), and 10μg / ml Brefeldin A (Sigma) was added within the last 6 hours. For surface staining, cells were labeled with anti-CD4-FITC (BD Biosciences) and anti-CD3-PerCPVio700 (Miltenyi Biotec) in culture medium containing 10% FCS. Then, cells were fixed and permeabilized using the Cytofix / Cytoperm Fixation / Permeabilization Kit (BD Biosciences) according to the manufacturer's instructions and stained with anti-IFN-γ APC (BD Biosciences) and anti-IL5-PE (Miltenyi Biotech).

[0090] qRT-PCR

[0091] For RNA extraction, the lungs were immersed in TRIzol reagent (Invitrogen) at harvest and immediately frozen with dry ice. After thawing, the lungs were homogenized using GentleMACS using the RNA 0.2 protocol. 200 μl of chloroform was added per ml of TRIZOL, and after vigorous vortexing, the tubes were centrifuged at 18,000 x g for 1 hour at 4 ° C. The upper aqueous phase containing eukaryotic RNA was recovered, added to 700 μl of isopropanol, and centrifuged at 18,000 x g for 10 minutes at 4 ° C. The resulting precipitate was washed with 70% EtOH and stored at -20 ° C. Residual DNA was removed by DNAse treatment, RNA was purified by phenol-acid-chloroform extraction, and precipitated ON with isopropanol and sodium acetate at -20 ° C. A cDNA library was constructed for gene expression analysis by RT-qPCR. The primer pairs used in this study are as follows:

[0092]

[0093] Atomization research

[0094] MTBVAC and BCG produced under GMP conditions were resuspended in 1 ml per vial and placed in the reservoir of a clinical nebulizer U100 (OMRON). The nebulizer was connected to a wash bottle filled with 5 ml of sterile water with a plastic tube and connected to a vacuum pump to recover the nebulized part. The bacteria were nebulized for 5 minutes, and the nebulized part and the reservoir part were spread on a solid agar 7H10 medium supplemented with ADC. The nebulization effect index was calculated as follows:

[0095]

[0096] statistics

[0097] Before starting the experimental procedures, commercial mice were randomly assigned to groups of 6 animals per cage. The results were analyzed without blinding. No statistical methods were used to calculate sample size in the animal experiments. Statistical analysis was performed using GraphPrism software. The statistical tests used for each experiment are shown in the figure legends. All statistical tests used were two-tailed. Grubb's test was applied to all data sets to determine outliers and was discarded from the final statistical analysis. Differences were considered significant at p values ​​< 0.05.

[0098] Example 1

[0099] In OVA-driven asthma ( Figure 1 A) and analyzed by flow cytometry ( Figure 1 B) Determine pulmonary eosinophilia ( Figure 1 In the acute model of B), sensitized mice were intranasally administered MTBVAC ( Figure 1 C) and BCG( Figure 1 D) The vaccine significantly reduced the percentage of allergen-induced eosinophilia to levels comparable to the negative control. This reduction was also observed when analyzing the total number of eosinophils, without significantly affecting other cell populations ( Figure 1 E. Figure 1 F). The effects of vaccine treatment were also observed when analyzing mucus secretion and lung epithelial remodeling, as observed by PAS staining. BCG-treated mice showed a much lower presence of goblet cells and mucus material, as well as a lower rate of epithelial proliferation ( Figure 1 G).

[0100] Example 2

[0101] Both BCG and MTBVAC reduced BAL in a dose-dependent manner ( Figure 2 A) and lungs ( Figure 2 In both cases, BAL showed eosinophilia at 10 6 In the lung, the highest tested dose (MTBVAC 10 7 CFU, BCG is 10 6 ) achieved negative control levels of eosinophilia.

[0102] Example 3

[0103] BCG primarily infects alveolar macrophages. BCG internalization leads to the expression of M1 polarization markers, such as iNOS or CD86 ( Figure 3 A). In addition, BCG infection upregulated M1 markers (iNOS or CD86) and downregulated M2 markers (CD206) in the total lung macrophage population ( Figure 3 B. Figure 3 C). Study of pulmonary gene expression of M1 markers iNOS and IL1b (higher in the BCG group) and M2 markers Ym1, Arg1, and retnla (lower in the BCG group) confirmed BCG-induced M1 repolarization of macrophages ( Figure 3 D).

[0104] Example 4

[0105] BCG intranasal administration rebalances the allergen-induced Th2 response toward a Th1 phenotype. BCG vaccination induces Th1-related genes, such as Ifng, Il12a, or the transcription factor Tbet. In contrast, genes encoding typical Th2 cytokines and chemokines, such as IL-5, IL-4, IL-13, or CCL-1, are downregulated by BCG ( Figure 4A). Consistent with these results, IL-5 and IL-4 cytokines were elevated in the BAL and lungs of the OVA group, respectively, while IFNγ was increased with BCG vaccination ( Figure 4 B. Figure 4 C).

[0106] When allergen-specific T cells were investigated, these changes were recapitulated following ex vivo OVA stimulation of lymphocytes harvested from mediastinal lymph nodes. The data showed that IL-4, IL-5, and IL-13 were higher in the OVA group compared with BCG-vaccinated mice, while OVA-specific production of IFNγ was lower ( Figure 4 D to Figure 4 G). Using intracellular staining and flow cytometry, we directly visualized cytokine-producing CD4+CD44+ T cells corresponding to the memory phenotype. After stimulation with CD3 / CD28 or OVA, the polarization of T cell responses was found to be opposite between the two groups. OVA-specific IL-5-producing cells were significantly reduced in mice treated with BCG ( Figure 4 H to Figure 4 I).

[0107] Example 5

[0108] MTBVAC treatment resulted in a decrease in the Th2 cytokine IL-5 and an increase in the Th1 marker IFNγ in the BAL of OVA-challenged mice ( Figure 5 A), and also in lymph node cells stimulated with OVA ex vivo ( Figure 5 B). MTBVAC administration abolished the expression of the M2 marker Arg1 in lung macrophages, whereas it induced the expression of the M1 marker iNOS ( Figure 5 C).

[0109] Example 6

[0110] MTBVAC and BCG abolished the eosinophilia established in the chronic model of OVA-driven asthma ( Figure 6 A) Vaccine administration to OVA-challenged mice after eosinophils have already infiltrated the respiratory tract ( Figure 6 B), then the eosinophils were reduced to a level equivalent to that of the negative control ( Figure 6 C. Figure 6 D). The effects of vaccine treatment were also observed when analyzing mucus secretion and lung epithelial remodeling, as observed by PAS staining. BCG-treated mice showed a much lower presence of goblet cells and mucus material, as well as a lower rate of epithelial proliferation ( Figure 6 E).

[0111] Example 7

[0112] MTBVAC and BCG abolished established eosinophilia in a chronic asthma model induced by the physiological allergen house dust mite (HDM). Figure 7 A) Administration of the vaccine to HDM-challenged mice, when eosinophils had already infiltrated the respiratory tract, significantly reduced eosinophils to levels comparable to those of negative controls ( Figure 7 B). The effects of vaccine treatment were also observed when analyzing mucus secretion and lung epithelial remodeling, as observed by PAS staining. BCG-treated mice showed a much lower presence of goblet cells and mucus material, as well as a lower rate of epithelial proliferation ( Figure 7 C).

[0113] Intranasal administration of MTBVAC and BCG rebalanced the HDM-induced Th2 response toward a Th1 phenotype. In both BAL and lymph node cells stimulated with allergens, the Th2 cytokines IL-5, IL-4, and IL-13 were reduced in the vaccine-treated group ( Figure 7 D. Figure 7 E). In contrast, MTBVAC and BCG increased the levels of the Th1 cytokine IFNγ-( Figure 7 F. Figure 7 G).

[0114] Example 8

[0115] Clinical Aerosol Device OMRON U100( Figure 8 A. Figure 8 The vaccine nebulization in B) demonstrated that the nebulization effect of MTBVAC was significantly higher than that of BCG. Approximately 15% of the MTBVAC bacteria initially placed in the nebulizer reservoir were nebulized, while in the case of BCG, the percentage dropped to 0.15% ( Figure 8 C to Figure 8 E). This suggests that achieving therapeutic doses in the lungs with MTBVAC is more feasible than with BCG by using aerosol as a pulmonary route of vaccine administration. Electron microscopy images of BCG and MTBVAC show the smaller size of MTBVAC ( Fig. 9 A. Fig. 9 B), which could explain the observed differences in atomization effects.

[0116] Example 9

[0117] Intranasal MTBVAC reduced OVA-challenge-induced eosinophilia in the esophagus ( Fig.10 This result suggests that in addition to allergic asthma, live attenuated vaccines may also be used to treat other types of eosinophilia, such as eosinophilic esophagitis (EoE).

[0118] Example 10

[0119] Compared with BCG administered by the classical subcutaneous route, pulmonary delivery of MTBVAC improves the protective efficacy of the vaccine against tuberculosis challenge ( Fig.11 ).

[0120] Embodiment 11

[0121] Resuspend MTBVAC and ONCOTICE GMP vials at 1 ml / vial and standardize the concentration to 10 7 CFU / ml, and 2 ml of each vaccine formulation was placed in the reservoir of the clinical nebulizer U100 (OMRON). There are strong regulatory safety concerns for intranasal delivery of vaccines in humans. However, aerosol administration is an accepted way to reach the pulmonary compartment in the clinic, and a variety of commercial nebulizers authorized for human use can be used. From a practical point of view, an important step in introducing pulmonary administration of live mycobacteria into clinical development is the feasibility of delivering therapeutic vaccine doses via the aerosol route. To evaluate this, we performed intranasal administration of live mycobacteria via the clinical nebulizer OMRON U100 ( Fig.12 A) The nebulization effect of GMP formulations of MTBVAC and BCG suitable for human use (ONCOTICE) was measured. We loaded the reservoir with MTBVAC or BCG resuspended in the corresponding eluent, placed the nebulizer in a horizontal position and connected it via a plastic tube to a wash bottle containing 5 ml of sterile water coupled to a vacuum pump, where the nebulized fraction was recovered. The bacterial density in the reservoir for both vaccines was approximately 1.5 × 10 7 CFU / ml. After nebulization for 1 minute, the average amount of bacteria recovered in the nebulized part was: MTBVAC was 1.85×10 6 CFU, BCG is 5×10 5 CFU( Fig.12 B). The average efficiency of aerosolization relative to the initial bacterial load in the reservoir was 11.7% for MTBVAC and 3.1% for ONCOTICE ( Fig.12 C).

[0122] We have identified certain characteristics of BCG and MTBVAC that could explain the differences observed in nebulization efficacy. Electron microscopy images showed that the bacterial length of MTBVAC was smaller (<1 μm) compared to BCG (>2 μm). Considering that the average particle size released by clinical nebulizers is approximately 5 μm, it can be speculated that agglomeration and bacterial size may have a crucial impact on the nebulization efficacy of different live vaccines. This physical difference in MTBVAC would make it more suitable for administration using a clinical nebulizer. Sequence Listing <110> University of Zaragoza <120> Therapeutic effects of live attenuated mycobacteria delivered via the lungs <130> 905 576 <160> 46 <170> PatentIn version 3.5 <210> 1 <211> 1752 <212> DNA <213> Artificial Sequence <220> <223> Wild-type fadD26 gene in Mt103 <220> <221> misc_feature <222> (1)..(1752) <400> 1 atgccggtga ccgaccgttc agtgccctct ttgctgcaag agagggccga ccagcagcct 60 gacagcactg catatacgta catcgactac ggatccgacc ccaagggatt tgctgacagc 120 ttgacttggt cgcaggtcta cagtcgtgca tgcatcattg ctgaagaact caagttatgc 180 gggttacccg gagatcgagt ggcggtttta gcgccacaag gactggaata tgtccttgca 240 ttcctgggcg cacttcaggc tggatttatc gcggttccgc tgtcaactcc acagtatggc 300 attcacgatg accgcgtttc tgcggtgttg caggattcca agccggtagc cattctcacg 360 acttcgtccg tggtaggcga tgtaacgaaa tacgcagcca gccacgacgg gcagcctgcc 420 ccggtcgtag ttgaggttga tctgcttgat ttggactcgc cgcgacagat gccggctttc 480 tctcgtcagc acaccggggc ggcttatctc caatacacgt ccggatcgac gcgtacgccg 540 gccggagtca ttgtgtcgca cacgaatgtc attgccaatg tgacacaaag tatgtacggc 600 tatttcggcg atcccgcaaa gattccgacc gggactgtgg tgtcgtggct gcctttgtat 660 cacgatatgg gcctgattct cggaatttgc gcaccgctgg tggcccgacg ccgcgcgatg 720 ttgatgagcc caatgtcatt tttgcgccgt ccggcccgct ggatgcaact gcttgccacc 780 agcggccggt gcttttctgc ggcaccgaat ttcgccttcg agctggccgt gcgcagaaca 840 tctgaccagg acatggcggg gctcgacctg cgcgacgtgg tcggcatcgt cagtggcagt 900 gagcgaatcc atgtggcaac cgtgcggcgg ttcatcgagc ggttcgcgcc gtacaatctc 960 agccccaccg cgatacggcc gtcgtacggg ctcgcggaag cgaccttata tgtggcagct 1020 cccgaagccg gcgccgcgcc caagacggtc cgttttgact acgagcagct gaccgccggg 1080 caggctcggc cctgcggaac cgatgggtcg gtcggcaccg aactgatcag ctacggctcc 1140 cccgacccat cgtctgtgcg aatcgtcaac ccggagacca tggttgagaa tccgcctgga gtggtcggtg agatctgggt gcatggcgac cacgtgacta tggggtattg gcagaagccg 1260. aagcagaccg cgcaggtctt cgacgccaag ctggtcgatc ccgcgccggc agccccggag 1320 gggccgtggc tgcgcaccgg cgacctgggc gtcatttccg atggtgagct gttcatcatg 1380 ggccgcatca aagacctgct catcgtggac gggcgcaacc actaccccga cgacatcgag gcaacgatcc aggagatcac cggtggacgg gccgcggcga tcgcagtgcc cgacgacatc accgaacaac tggtggcgat catcgaattc aagcgacgcg gtagtaccgc cgaagaggtc atgctcaagc tccgctcggt gaagcgtgag gtcacctccg cgatatcgaa gtcacacagc 1620. ctgcgggtgg ccgatctcgt tctggtgtca cctggttcga ttcccatcac caccagcggc 1680. aagatccggc ggtcagcctg cgtcgaacgc tatcgcagcg acggcttcaa gcggctggac 1740. gtagccgtat of 1752 <210> 2 <211> 410 <212> DNA <213> Artificial Sequence <220> <223> fadD26 in MTBVAC <220> <221> misc_feature <222> (1)..(410) <400> 2 atgccggtga ccgaccgttc agtgccctct ttgctgcaag agagggccga ccagcagcct 60 gacagcactg catatacgta catcgactac ggatccacta gttctagagc aaccgtccga 120 aatattataa attatcgcac acataaaaac agtgctgtta atgtgtctat taaatcgatt 180 ttttgttata acagacactg cttgtccgat atttgattta ggatacattt ttatgagatc 240 ccccgggctg caggaattcg atatcgaagt cacacagcct gcgggtggcc gatctcgttc 300 tggtgtcacc tggttcgatt cccatcacca ccagcggcaa gatccggcgg tcagcctgcg 360 tcgaacgcta tcgcagcgac ggcttcaagc ggctggacgt agccgtatga 410 <210> 3 <211> 744 <212> DNA <213> Artificial Sequence <220> <223> Wild-type phoP gene in Mt103 <220> <221> misc_feature <222> (1)..(744) <400> 3 atgcggaaag gggttgatct cgtgacggcg ggaaccccag gcgaaaacac cacaccggag 60 gctcgtgtcc tcgtggtcga tgatgaggcc aacatcgttg aactgctgtc ggtgagcctc 120 aagttccagg gctttgaagt ctacaccgcg accaacgggg cacaggcgct ggatcgggcc 180 cgggaaaccc ggccggacgc ggtgatcctc gatgtgatga tgcccgggat ggacggcttt 240 ggggtgctgc gccggctgcg cgccgacggc atcgatgccc cggcgttgtt cctgacggcc 300 cgtgactcgc tacaggacaa gatcgcgggt ctgaccctgg gtggtgacga ctatgtgaca 360 aagcccttca gtttggagga ggtcgtggcc aggctgcggg tcatcctgcg acgcgcgggc 420 aagggcaaca aggaaccacg taatgttcga ctgacgttcg ccgatatcga gctcgacgag 480 gagacccacg aagtgtggaa ggcgggccaa ccggtgtcgc tgtcgcccac cgaattcacc 540 ctgctgcgct atttcgtgat caacgcgggc accgtgctga gcaagcctaa gattctcgac 600 cacgtttggc gctacgactt cggtggtgat gtcaacgtcg tcgagtccta cgtgtcgtat 660 ctgcgccgca agatcgacac tggggagaag cggctgctgc acacgctgcg cggggtgggc 720 tacgtactgc gggagcctcg atga 744 <210> 4 <211> 819 <212> DNA <213> Artificial Sequence <220> <223> Truncated phoP in MTBVAC <220> <221> misc_feature <222> (1)..(819) <400> 4 atgcggaaag gggttgatct cgtgacggcg ggaaccccag gcgaaaacac cacaccggag 60 gctcgtgtcc tcgtggtcga tgatgaggcc aacatcgttg aactgctgtc ggtgagcctc 120 aagttccagg gctttgaagt ctacaccgcg accaacgggg cacaggcgct ggatcgggcc 180 cgggaaaccc ggccggacgc ggtgatcctc gatgtgatga tgcccgggat ggacggcttt 240 ggggtgctgc gccggctgcg cgccgacggc atcgatgccc cggcgttgtt cctgacggcc 300 cgtgactcgc tacaggacaa gatcgcgggt ctgaccctgg gtggtgacga ctatgtgaca 360 aagcccttca gtttggagga ggtcgtggcc aggctgcggg tcatcctgcg acgcgcgggc 420 aagggcaaca aggaaccacg taatgttcga ctgacgttcg ccgatatcga attcctgcag 480 cccgggggat ctcataaaaa tgtatcctaa atcaaatatc ggacaagcag tgtctgttat 540 aacaaaaaat cgatttaata gacacattaa cagcactgtt tttatgtgtg cgataattta 600 taatatttcg gacggttgct ctagaactag tggatcaacg cgggcaccgt gctgagcaag 660 cctaagattc tcgaccacgt ttggcgctac gacttcggtg gtgatgtcaa cgtcgtcgag 720 tcctacgtgt cgtatctgcg ccgcaagatc gacactgggg agaagcggct gctgcacacg 780 ctgcgcgggg tgggctacgt actgcgggag cctcgatga 819 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer actin <220> <221> misc_feature <222> (1)..(20) <400> 5 accagttcgc catggatgac 20 <210> 6 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer actin <220> <221> misc_feature <222> (1)..(16) <400> 6 tgccggagcc gttgtc 16 <210> 7 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Forward primer 18S <220> <221> misc_feature <222> (1)..(19) <400> 7 ttcgtattgc gccgctaga 19 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer 18S <220> <221> misc_feature <222> (1)..(20) <400> 8 ctttcgctct ggtccgtctt 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Gata3 <220> <221> misc_feature <222> (1)..(20) <400> 9 gacccgaaac cggaagatgt 20 <210> 10 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Gata3 <220> <221> misc_feature <222> (1)..(18) <400> 10 gcgcgtcatg cacctttt 18 <210> 11 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Il12a <220> <221> misc_feature <222> (1)..(21) <400> 11 acgcagcact tcagaatcac a 21 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Il12a <220> <221> misc_feature <222> (1)..(20) <400> 12 caccagcatg cccttgtcta 20 <210> 13 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Il12b <220> <221> misc_feature <222> (1)..(19) <400> 13 tggagcactc cccattcct 19 <210> 14 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Il12b <220> <221> misc_feature <222> (1)..(18) <400> 14 tgcgctggat tcgaacaa 18 <210> 15 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Foward primer Ifng <220> <221> misc_feature <222> (1)..(20) <400> 15 ttggctttgc agctcttcct 20 <210> 16 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Ifng <220> <221> misc_feature <222> (1)..(19) <400> 16 tgactgtgcc gtggcagta 19 <210> 17 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Il5 <220> <221> misc_feature <222> (1)..(23) <400> 17 ttgacaagca atgagacgat gag 23 <210> 18 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Il5 <220> <221> misc_feature <222> (1)..(22) <400> 18 tccaatgcat agctggtgat tt 22 <210> 19 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Foward primer Il4 <220> <221> misc_feature <222> (1)..(20) <400> 19 ggagatggat gtgccaaacg 20 <210> 20 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Il4 <220> <221> misc_feature <222> (1)..(22) <400> 20 cgagctcact ctctgtggtg tt 22 <210> 21 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Il13 <220> <221> misc_feature <222> (1)..(22) <400> 21 ttgaggagct gagcaacatc ac 22 <210> 22 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Il13 <220> <221> misc_feature <222> (1)..(16) <400> 22 ccatgctgcc gttgca 16 <210> 23 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Stat1 <220> <221> misc_feature <222> (1)..(21) <400> 23 ctctggaatg atgggtgcat t 21 <210> 24 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Revese primer Stat1 <220> <221> misc_feature <222> (1)..(19) <400> 24 ttgagcagag cgcgttctc 19 <210> 25 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Stat4 <220> <221> misc_feature <222> (1)..(21) <400> 25 catttgcaac ccaaggagat g 21 <210> 26 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Stat4 <220> <221> misc_feature <222> (1)..(17) <400> 26 tggcagccct cgtttcc 17 <210> 27 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Stat6 <220> <221> misc_feature <222> (1)..(22) <400> 27 aactgcaacg gctctatgtt ga 22 <210> 28 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Stat6 <220> <221> misc_feature <222> (1)..(20) <400> 28 agccagtcag ccaggagatg 20 <210> 29 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Tnf <220> <221> misc_feature <222> (1)..(20) <400> 29 cagccgatgg gttgtacctt 20 <210> 30 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Tnf <220> <221> misc_feature <222> (1)..(18) <400> 30 ggcagccttg tcccttga 18 <210> 31 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Forward primer T Bet <220> <221> misc_feature <222> (1)..(22) <400> 31 acctgttgtg gtccaagttc aa 22 <210> 32 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer T Bet <220> <221> misc_feature <222> (1)..(21) <400> 32 gccgtccttg cttagtgatg a 21 <210> 33 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Ifnb1 <220> <221> misc_feature <222> (1)..(22) <400> 33 ccctatggag atgacggaga ag 22 <210> 34 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Ifnb1 <220> <221> misc_feature <222> (1)..(21) <400> 34 gagcatctct tggatggcaa a 21 <210> 35 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer CC111 <220> <221> misc_feature <222> (1)..(20) <400> 35 gaccaggttg ggcaaagaga 20 <210> 36 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer CC111 <220> <221> misc_feature <222> (1)..(20) <400> 36 ggcatcctgg acccacttct 20 <210> 37 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Ym1 <220> <221> misc_feature <222> (1)..(18) <400> 37 gtctggcccc tggacatg 18 <210> 38 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Ym1 <220> <221> misc_feature <222> (1)..(23) <400> 38 agagggaaat gtctctggtg aca 23 <210> 39 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Il1b <220> <221> misc_feature <222> (1)..(20) <400> 39 agttgacgga ccccaaaaga 20 <210> 40 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Il1b <400> 40 ggacagccca ggtcaaagg 19 <210> 41 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Retnla <220> <221> misc_feature <222> (1)..(20) <400> 41 cagctgatgg tcccagtgaa 20 <210> 42 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Rtnla <220> <221> misc_feature <222> (1)..(24) <400> 42 ttccttgacc ttattctcca cgat 24 <210> 43 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Forward primer Nos2 <220> <221> misc_feature <222> (1)..(19) <400> 43 ggatcttccc aggcaacca 19 <210> 44 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Revese primer Nos2 <220> <221> misc_feature <222> (1)..(21) <400> 44 tccacaactc gctccaagat t 21 <210> 45 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> Primer Forward Arg1 <220> <221> misc_feature <222> (1)..(22) <400> 45 gctccaagcc aaagtcctta ga 22 <210> 46 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer Arg1 <220> <221> misc_feature <222> (1)..(20) <400> 46 cctcgaggct gtccttttga 20

Claims

1. Use of a live attenuated Mycobacterium tuberculosis (M. tuberculosis) composition in the preparation of a medicament for use as a preventive agent for a subject at risk of suffering from allergic asthma or a subject at risk of developing allergic asthma, wherein the composition comprises an isolated microorganism belonging to the MTBVAC strain of Mycobacterium tuberculosis, the isolated microorganism having: i) a PhoP- phenotype inactivated by genetic deletion of the Rv0757 gene, wherein the open reading frame sequence of PhoP consists of SEQ ID NO 4; and ii) a deletion of a second gene Rv2930 (fadD26) that prevents the production of tuberculin alcohol wax chorismate, wherein the open reading frame sequence of fadD26 consists of SEQ ID NO 2, in, The composition is administered to the subject by inhalation using aerosol technology.

2. The use according to claim 1, in, The composition is a lyophilized composition further comprising a stabilizer, a bulking agent or a buffer.